Project Details
Key findings
Daily administration of the TRPV1 antagonist ABT-102 over 9 days did not cause significant hyperthemia in STZ-diabetic rats from days 2-9, but did significantly reverse the static allodynia associated with diabetic neuropathy (in line with pregabalin efficacy), confirming the hypothesis that TRPV1 function is altered peripherally in diabetes. These data demonstrate that there is a potential for treatment of diabetic neuropathy by TRPV1 antagonists.
Key data will be presented at the BPS Pharmacology conference (London, 2017) and is to be submitted to a peer reviewed pain journal.
Key data will be presented at the BPS Pharmacology conference (London, 2017) and is to be submitted to a peer reviewed pain journal.
| Status | Finished |
|---|---|
| Effective start/end date | 7/06/17 → 25/07/17 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.